Dr Manur Gururajachar Janaki, Senior Consultant – Department of Radiation Oncology, Ramaiah Institute of Oncology, Ramaiah Memorial Hospital, Bengaluru
Human papillomavirus (HPV) is one of the most frequent sexually transmitted viruses in India, and specific HPV strains have been linked to cervical cancer, one of the main causes of cancer-related deaths among women in the country. The introduction of HPV vaccines in India has provided a new ray of hope in the fight against this preventable malignancy, offering an effective strategy for lowering the burden of cervical cancer and improving public health.
-------------------------------------------------------------------------
The introduction of HPV vaccines in India has provided a new ray of hope in the fight against this preventable malignancy, offering an effective strategy for lowering the burden of cervical cancer and improving public health.
-------------------------------------------------------------------------
Impact of HPV vaccines
HPV vaccines like Gardasil and Cervarix are extremely successful at preventing infections caused by high-risk HPV strains, particularly HPV-16 and HPV-18. These two account for most cervical cancer incidences in India. Cervical precancerous changes and HPV infection rates have dropped dramatically in areas where HPV vaccination programs are in place.
The efficacy of HPV vaccines in preventing cervical cancer emphasizes the necessity of vaccination programs and provides a substantial potential for healthcare enterprises and organisations to assist the scale of these activities across India. Along with regular pap smear screening, these vaccines have the potential to significantly reduce the incidence of cervical cancer nationwide.
------------------------------------------------------------------------
Cervical precancerous changes and HPV infection rates have dropped dramatically in areas where HPV vaccination programs are in place.
The efficacy of HPV vaccines in preventing cervical cancer emphasizes the necessity of vaccination programs and provides a substantial potential for healthcare enterprises and organizations to assist scale of these activities across India.
--------------------------------------------------------------------------
Challenges in HPV vaccine
The adoption of HPV vaccines in India is hampered by several factors, despite their shown advantages. Many rural women are unaware of the connection between HPV and cervical cancer while women from metropolitan cities get a lot of false information from various digital media. Additionally, many women find it difficult to get vaccinated due to the high cost of vaccines and restricted access to healthcare infrastructure.
To ensure the success of HPV vaccination programs in India, government entities, healthcare providers, and companies must work together and promote awareness, reduce prices, and improve vaccine access. Working together, we can ensure that the women who need the vaccine the most, particularly those living in rural and underserved areas, get access to this life-saving medicine.
---------------------------------------------------------------------------
To ensure the success of HPV vaccination programs in India, government entities, healthcare providers, and companies must work together and promote awareness, reduce prices, and improve vaccine access.
--------------------------------------------------------------------------
Innovations shaping the future
Several developments in HPV vaccination research have created chances for growth and partnership in India's healthcare industry. These advancements have the potential to improve vaccine accessibility and efficacy, benefiting both enterprises and public health initiatives.
Here are some major developments:
- Next-Generation Vaccines - Researchers in India are developing HPV vaccines to work against many more strains of this virus. While current vaccines like Gardasil 9 cover several high-risk HPV strains, future vaccines may offer even wider protection. This research aims to create vaccines that better meet the needs of Indian communities.
- Therapeutic Vaccines - Therapeutic vaccinations are intended to treat precancers and current HPV infections, whereas preventative vaccines are crucial in halting HPV infections before they can cause cancer. These vaccines, which are still in the trial phase, could offer new hope for women who are already infected with HPV, providing an opportunity to treat or even eliminate early-stage cancers. This area of research could open new business opportunities in India’s growing biotechnology sector.
- Single-Dose Vaccines - According to research, a single-dose HPV vaccine is as effective as the current two- or three-dose regimens. This might significantly lower the costs and logistical challenges of immunisation campaigns in India, particularly in rural areas with limited healthcare access, making the vaccine more acceptable.
- mRNA Technology - The effectiveness of mRNA vaccines in the COVID-19 pandemic has sparked interest in applying mRNA technology to HPV vaccinations. This method could result in faster production times and enhanced vaccine efficacy, which would be especially advantageous in India, where vaccine demand is higher and efficient production is crucial.
Addressing Equity in Vaccination
The success of India's vaccination campaigns depends on ensuring that everyone has fair access to HPV vaccines. All women must have access to these vaccines, especially in rural regions where cervical cancer rates are high. This requires collaboration between the government, medical professionals, and industry partners. Efforts to reduce vaccine costs, enhance supply chains, and raise awareness will be critical for narrowing access gaps. Businesses in the healthcare industry play a significant role in facilitating vaccine delivery. They can assist by proposing novel ways to improve distribution networks, better tracking systems, and ensure vaccines reach women in need.
----------------------------------------------------------------------------
Efforts to reduce vaccine costs, enhance supply chains, and raise awareness will be critical for narrowing access gaps. They can assist by proposing novel ways to improve distribution networks, better tracking systems, and ensure vaccines reach women in need.
---------------------------------------------------------------------------
The future of HPV vaccines in India seems promising. Continued breakthroughs in vaccine research, dissemination, and public health efforts will be critical in avoiding cervical cancer. For healthcare organizations, this is an opportunity to achieve radical change while extending their market presence.
My take on this topic is this- HPV vaccination should be a part of the national universal Immunization programme and is to be included along with all other vaccines that we give since birth to both girls and boys. It is very much possible as it is best given between 9 and 14 years of age. Then it will be possible to eradicate cervical cancer in India. Meanwhile, we should focus on providing vaccination to every woman in need, regardless of where she lives by making investments in infrastructure, research, and cooperation. These are the steps to ensure that Indian women have a healthier, cervical cancer-free future.
